Showing 3591-3600 of 20919 results for "".
- Increased Use of Paxlovid Could Cut Hospitalizations, Deaths, and Costshttps://reachmd.com/news/increased-use-of-paxlovid-could-cut-hospitalizations-deaths-and-costs/2457310/Increased use of Paxlovid, the antiviral drug used to treat COVID-19, could prevent hundreds of thousands of hospitalizations and save tens of billions of dollars a year, according to a new epidemiological model published by researchers at The University of Texas at Austin. In
- Diagnosis, Clinical Trials and Treatments for Inherited Retinal Diseaseshttps://reachmd.com/news/diagnosis-clinical-trials-and-treatments-for-inherited-retinal-diseases/2457281/Oct. 14, 2023 Inherited retinal diseases (IRDs) vary widely, but most of them lead to progressive and profound visual symptoms. Timely diagnosis, counseling and resource discussions are imperative to improve quality of life
- Usefulness of Belimumab in Adult Patients with Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Reviewhttps://reachmd.com/news/usefulness-of-belimumab-in-adult-patients-with-systemic-lupus-erythematosus-evaluated-using-single-indexes-a-meta-analysis-and-systematic-review/2457293/Belimumab is the first antibody drug approved for systemic lupus erythematosus (SLE), and is a fully human monoclonal antibody that inhibits soluble B lymphocyte stimulator protein. In clinical trials, a composite index was used to assess efficacy of belimumab. H
- Notre Dame Receives Chan Zuckerberg Initiative Award for Neurodegenerative Disease Researchhttps://reachmd.com/news/notre-dame-receives-chan-zuckerberg-initiative-award-for-neurodegenerative-disease-research/2457256/The University of Notre Dame has received a Collaborative Pairs Pilot Project Award from the Chan Zuckerberg Initiative to study genes that affect neurodegenerative diseases, such as Alzheimer’s disease. This is Notre Dame’s first award from the Chan Zuckerberg Initiative. The awa
- Can Dietary Patterns Impact Stomach Cancer Risk?https://reachmd.com/news/can-dietary-patterns-impact-stomach-cancer-risk/2457271/In a recent review published in Frontiers in Oncology, researchers investigated eating patterns and indices related to
- Biden Administration Unveils HCV Initiative: A Significant Step Towards Public Healthhttps://reachmd.com/news/biden-administration-unveils-hcv-initiative-a-significant-step-towards-public-health/2457280/For decades, many Americans with hepatitis C have struggled to get into the continuum of care. And unfortunately, some have died waiting for treatment that remains to be sometimes inaccessible or egregiously expensive in the United States. Within the Biden administration’s proposed budg
- Paresthesia Symptoms Negatively Impact Spinal Surgery Satisfaction: Studyhttps://reachmd.com/news/paresthesia-symptoms-negatively-impact-spinal-surgery-satisfaction-study/2457246/A recent study has revealed that paresthesia symptoms can have a significant negative impact on patient satisfaction following spinal surgery. Paresthesia refers to abnormal sensations such as tingling, numbness, or burning that are often experienced in the extrem
- Study Reveals High Number of Persistent COVID-19 Infections in the General Populationhttps://reachmd.com/news/study-reveals-high-number-of-persistent-covid-19-infections-in-the-general-population/2457262/The study was based on data from the ONS Covid Infection Survey, the largest regular survey of COVID-19 infections in the general population. Image credit: Michele Ursi, Getty Images. It has long been thought that prolonged COVID-19 infect
- Scientists Improve Materials for Reconstructive and Plastic Surgeryhttps://reachmd.com/news/scientists-improve-materials-for-reconstructive-and-plastic-surgery/2457245/(Left) Classical magnetic resonance imaging of a rat (¹H MRI), a transverse section at approximately the waist. The red arrow points to the implantation site of the new (fluorinated) implant
- Galderma Announces Filing Acceptance for Investigational Prurigo Nodularis and AD Treatmenthttps://reachmd.com/news/galderma-announces-filing-acceptance-for-investigational-prurigo-nodularis-and-ad-treatment/2457240/Galderma announced the acceptance of its Biologics License Applications for nemolizumab, a first-in-class monoclonal antibody IL-31 inhibitor, for the treatment of prurigo nodularis in adults and adolescents with moderate-to-severe atopic dermatitis (AD)